These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15118573)

  • 1. Side effects of medical therapy for chronic hepatitis C.
    Shiffman ML
    Ann Hepatol; 2004; 3(1):5-10. PubMed ID: 15118573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
    Hunyady B; Kovács B; Battyáni Z
    Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
    Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
    N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
    Hadziyannis SJ; Sette H; Morgan TR; Balan V; Diago M; Marcellin P; Ramadori G; Bodenheimer H; Bernstein D; Rizzetto M; Zeuzem S; Pockros PJ; Lin A; Ackrill AM;
    Ann Intern Med; 2004 Mar; 140(5):346-55. PubMed ID: 14996676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
    N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.
    McHutchison JG; Manns M; Patel K; Poynard T; Lindsay KL; Trepo C; Dienstag J; Lee WM; Mak C; Garaud JJ; Albrecht JK;
    Gastroenterology; 2002 Oct; 123(4):1061-9. PubMed ID: 12360468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.
    Shiffman ML; Di Bisceglie AM; Lindsay KL; Morishima C; Wright EC; Everson GT; Lok AS; Morgan TR; Bonkovsky HL; Lee WM; Dienstag JL; Ghany MG; Goodman ZD; Everhart JE;
    Gastroenterology; 2004 Apr; 126(4):1015-23; discussion 947. PubMed ID: 15057741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
    Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
    Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of peginterferon alpha-2a/ribavirin in treatment-naive Cameroonian patients with chronic hepatitis C.
    Njouom R; Sartre MT; Timba I; Nerrienet E; Tchendjou P; Pasquier C; Rousset D
    J Med Virol; 2008 Dec; 80(12):2079-85. PubMed ID: 19040282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superiority of peginterferon α-2a and ribavirin combination over peginterferon α-2a monotherapy in the management of hemodialysis patients with chronic Hepatitis C virus infection.
    Al-Ghamdi SMG; Alaulaqi N; Al-Amoudi AA; Alghamdi A; Zagnoon A; Sadiq BB
    Saudi J Kidney Dis Transpl; 2017; 28(4):799-805. PubMed ID: 28748882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spotlight on peginterferon-alpha-2a (40 kD) plus ribavirin in the management of chronic hepatitis C mono-infection.
    Keam SJ; Cvetković RS
    BioDrugs; 2009; 23(1):63-8. PubMed ID: 19344193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C.
    Castera L; Constant A; Henry C; Champbenoit P; Bernard PH; De Ledinghen V; Demotes-Mainard J; Couzigou P
    Aliment Pharmacol Ther; 2006 Oct; 24(8):1223-30. PubMed ID: 17014581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin.
    Collantes RS; Younossi ZM
    J Clin Gastroenterol; 2005 Jan; 39(1 Suppl):S9-13. PubMed ID: 15597026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Side effects of therapy for chronic hepatitis C.
    Russo MW; Fried MW
    Gastroenterology; 2003 May; 124(6):1711-9. PubMed ID: 12761728
    [No Abstract]   [Full Text] [Related]  

  • 16. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial.
    Jensen DM; Marcellin P; Freilich B; Andreone P; Di Bisceglie A; Brandão-Mello CE; Reddy KR; Craxi A; Martin AO; Teuber G; Messinger D; Thommes JA; Tietz A
    Ann Intern Med; 2009 Apr; 150(8):528-40. PubMed ID: 19380853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peginterferon and ribavirin for hepatitis C.
    Ben Salem C; Hmouda H; Bouraoui K
    N Engl J Med; 2007 Mar; 356(12):1270; author reply 1271. PubMed ID: 17380578
    [No Abstract]   [Full Text] [Related]  

  • 18. Pernicious anemia during peginterferon-alpha2b plus ribavirin therapy for chronic hepatitis C.
    Musialik J; Petelenz M; Błoñska-Fajfrowska B; Hartleb M
    Eur J Gastroenterol Hepatol; 2009 May; 21(5):593-4. PubMed ID: 19194303
    [No Abstract]   [Full Text] [Related]  

  • 19. Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents.
    Mac Nicholas R; Norris S
    Aliment Pharmacol Ther; 2010 May; 31(9):929-37. PubMed ID: 20175767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial.
    Hayashi N; Izumi N; Kumada H; Okanoue T; Tsubouchi H; Yatsuhashi H; Kato M; Ki R; Komada Y; Seto C; Goto S
    J Hepatol; 2014 Aug; 61(2):219-27. PubMed ID: 24727123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.